These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 32450099)
1. Low prevalence of late-onset neutropenia after rituximab treatment in patients with pemphigus. Boch K; Zillikens D; Langan EA; Schmidt E; Ludwig RJ J Am Acad Dermatol; 2020 Dec; 83(6):1824-1825. PubMed ID: 32450099 [No Abstract] [Full Text] [Related]
2. Regulatory B10 Cells Increase after Rituximab Therapy but Not after Conventional Immunosuppression in Patients with Pemphigus. Chen A; Yoshizaki A; Miyagaki T; Streilein RD; Tedder TF; Hall RP J Invest Dermatol; 2021 Feb; 141(2):443-446. PubMed ID: 32628952 [No Abstract] [Full Text] [Related]
3. Anti-desmoglein-1 levels as predictor of prednisolone tapering in pemphigus vulgaris patients treated with rituximab. Balighi K; Sakhi RS; Daneshpazhooh M; Mahmoudi H; Teimourpour A; Tavakolpour S Dermatol Ther; 2018 Nov; 31(6):e12671. PubMed ID: 30246907 [No Abstract] [Full Text] [Related]
4. Early onset neutropenia and thrombocytopenia following rituximab in lupus nephritis. Shah S; Kavadichanda CG; Belani P; Ganesh RN; Negi VS Int J Rheum Dis; 2019 May; 22(5):946-950. PubMed ID: 30168270 [TBL] [Abstract][Full Text] [Related]
5. Rituximab-Related Late-Onset Neutropenia in Kidney Transplant Recipients Treated for Antibody-Mediated Acute Rejection. Ahmadi F; Dashti-Khavidaki S; Khatami MR; Lessan-Pezeshki M; Khalili H; Khosravi M Exp Clin Transplant; 2017 Aug; 15(4):414-419. PubMed ID: 27796249 [TBL] [Abstract][Full Text] [Related]
6. What is novel in the clinical management of pemphigus. Bilgic A; Murrell DF Expert Rev Clin Pharmacol; 2019 Oct; 12(10):973-980. PubMed ID: 31550941 [No Abstract] [Full Text] [Related]
7. Rituximab therapy in pemphigus: A long-term follow-up. Loi C; Magnano M; Ravaioli GM; Sacchelli L; Patrizi A; Bardazzi F Dermatol Ther; 2019 Jan; 32(1):e12763. PubMed ID: 30288877 [No Abstract] [Full Text] [Related]
8. Quality of life remains poor for patients with pemphigus vulgaris despite targeted therapies. Schultz B; Latour E; Fett N Br J Dermatol; 2019 Nov; 181(5):1101-1103. PubMed ID: 31127954 [No Abstract] [Full Text] [Related]
9. Low-dose rituximab and concurrent adjuvant therapy for pemphigus: Protocol and single-centre long-term review of nine patients. Robinson AJ; Vu M; Unglik GA; Varigos GA; Scardamaglia L Australas J Dermatol; 2018 Feb; 59(1):e47-e52. PubMed ID: 28211049 [TBL] [Abstract][Full Text] [Related]
10. Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study. Kanwar AJ; Vinay K; Sawatkar GU; Dogra S; Minz RW; Shear NH; Koga H; Ishii N; Hashimoto T Br J Dermatol; 2014 Jun; 170(6):1341-9. PubMed ID: 24640990 [TBL] [Abstract][Full Text] [Related]
11. Incidence of late onset neutropenia associated with rituximab use in B cell lymphoma patients undergoing autologous stem cell transplantation. Ha VH; Ghosh S; Leyshon C; Ryan N; Chambers CR; Stewart DA J Oncol Pharm Pract; 2018 Jul; 24(5):323-331. PubMed ID: 28358279 [TBL] [Abstract][Full Text] [Related]
12. Rituximab-related late-onset neutropenia in patients with rheumatic diseases: successful re-challenge of the treatment. Reitblat T; Wechsler A; Reitblat O Am J Case Rep; 2015 Apr; 16():211-4. PubMed ID: 25855510 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant rituximab treatment for pemphigus: A retrospective study of 45 patients at a single center with long-term follow up. Kim TH; Choi Y; Lee SE; Lim JM; Kim SC J Dermatol; 2017 Jun; 44(6):615-620. PubMed ID: 28186358 [TBL] [Abstract][Full Text] [Related]
14. "Change over time in the treatment of pemphigus vulgaris between 2004 and 2016 in Iran": A multiple cross-sectional study. Salarvand F; Fatehi Z; Shahali M; Balighi K; Ghiasi M; Abedini R; Mahmoudi H; Tavakolpour S; Chams-Davatchi C; Daneshpazhooh M Dermatol Ther; 2019 Mar; 32(2):e12827. PubMed ID: 30659718 [No Abstract] [Full Text] [Related]
15. Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome. Fujinaga S; Ozawa K; Sakuraya K; Yamada A; Shimizu T Clin Nephrol; 2016 Jun; 85(6):340-5. PubMed ID: 27125626 [TBL] [Abstract][Full Text] [Related]
16. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. Leshem YA; Hodak E; David M; Anhalt GJ; Mimouni D J Am Acad Dermatol; 2013 Mar; 68(3):404-11. PubMed ID: 23044076 [TBL] [Abstract][Full Text] [Related]
17. Unexpected B lymphocytes depletion in a patient with pemphigus vulgaris after a single dose of 50 mg rituximab. Wang R; Li R; Wang M J Dermatol; 2024 Oct; 51(10):e365-e366. PubMed ID: 38775209 [No Abstract] [Full Text] [Related]
18. Rituximab and intravenous immunoglobulin as alternatives to long-term systemic corticosteroids in the treatment of pemphigus: a single center case series of 63 patients. Brown AE; Motaparthi K; Hsu S Dermatol Online J; 2018 Jan; 23(12):. PubMed ID: 29447653 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of rituximab for autoimmune neutropenia: a French case series and literature review. Bigot W; Viallard JF; Sellam J; Dellal A; Retbi A; Gobert D; Malard F; Mohty M; Mekinian A; Fain O Rheumatology (Oxford); 2020 Sep; 59(9):2637-2640. PubMed ID: 32083652 [No Abstract] [Full Text] [Related]
20. Clinical efficacy of rituximab in the treatment of pemphigus: A retrospective study. Sharma VK; Bhari N; Gupta S; Sahni K; Khanna N; Ramam M; Sethuraman G Indian J Dermatol Venereol Leprol; 2016; 82(4):389-94. PubMed ID: 27279296 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]